Oncologic Outcome after Pulmonary Metastasectomy as Part of Multidisciplinary Treatment in a Tertiary Oncological Center

• Published in: Diagnostics (Basel) 2023-01, Vol.13 (1), p.165
• Main Authors: Motas, Natalia, Davidescu, Mihnea Dan, Tanase, Bogdan Cosmin, Rus, Ovidiu, Burlacu, Alin Ionut, Alexe, Vlad, Manolache, Veronica, Mizea, Madalina Cristiana, Gheorghiu, Nicolae, Trifanescu, Oana Gabriela, Gales, Laurentia Nicoleta, Horvat, Teodor, Anghel, Rodica Maricela
• Format: Article
• Language: English
• Subjects: Cancer therapies; Care and treatment; Chest; Consent; Development and progression; Diagnosis; Ewings sarcoma; Histology; Immunotherapy; LASER metastasectomy; Lung cancer; lung metastasectomy; Lymphatic system; Medical prognosis; Metastasis; metastatic cancer; MITS minimally invasive thoracic surgery; Ostomy; Pathology; Patients; pulmonary metastases; Surgery; Survival analysis; Thoracic surgery; Tumors; uniportal VATS video-assisted thoracic surgery
• ISSN: 2075-4418; 2075-4418
• DOI: 10.3390/diagnostics13010165

(1) Background: Pulmonary metastases are encountered in approximately one-third of patients with malignancies, especially from colorectal, lung, breast, and renal cancers, and sarcomas. Pulmonary metastasectomy is the ablative approach of choice, when possible, as part of the multidisciplinary effort to integrate and personalize the oncological treatment. (2) Methods: The study includes 58 consecutive cases of pulmonary metastasectomies, retrospectively analyzed, performed in 12 consecutive months, in which the pathology reports confirmed lung metastases. (3) Results: Most frequent pathological types of metastases were: 14 of colorectal cancer, 10 breast, 8 lung, and 8 sarcomas. At the time of primary cancer diagnosis, 14 patients (24.14%) were in the metastatic stage. The surgical approach was minimally invasive through uniportal VATS (Video-Assisted Thoracic Surgery) in 3/4 of cases (43 patients, 74%). Almost 20% of resections were typical (lobectomy, segmentectomy). Lymphadenectomy was associated in almost 1/2 of patients and lymph node metastases were found in 11.11% of cases. The mortality rate (intraoperative and 90 days postoperative) is zero. The OS after pulmonary metastasectomy is 87% at 18 months, and the estimated OS for cancer is 90% at 5 years. The worst outcome presents the patients with sarcomas and the best outcome-colorectal and lung cancer. The patients with 1 or 2 resected metastases presented 96% survival at 24 months. (4) Conclusions: After pulmonary metastasectomy, survival is favored by the small number of metastases resected (1 or 2), and by the dimension of metastases under 20.5 mm. The non-anatomic (wedge) type of lung resection may present a lower risk of death compared to lobectomy. No statistical significance on survival has the presence of lymphadenectomy, the laterality right/left lung, the upper/lower lobes. In the future, longer follow-up and prospective randomized trials are needed for drawing definitive conclusions.